As of Jul 31
| +1.39 / +3.81%|
The 2 analysts offering 12-month price forecasts for Anika Therapeutics Inc have a median target of 50.75, with a high estimate of 57.00 and a low estimate of 44.50. The median estimate represents a +33.91% increase from the last price of 37.90.
The current consensus among 2 polled investment analysts is to Buy stock in Anika Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.